AB033. SOH24AB_089. Assessing the clinical utility of preoperative neutrophil-lymphocyte ratio as a predictor of clinicopathological parameters in patients being treated for primary breast cancer
Clinical Breast Session

AB033. SOH24AB_089. Assessing the clinical utility of preoperative neutrophil-lymphocyte ratio as a predictor of clinicopathological parameters in patients being treated for primary breast cancer

Burce Isik1, Matthew Davey2, Alisha Jaffer1,2, Juliette Buckley2, Chwanrow Baban2, Bridget Anne Merrigan2, Shona Tormey2

1School of Medicine, University of Limerick, Castletroy, Limerick, Ireland; 2Symptomatic Breast Unit, University Hospital Limerick, Dooradoyle, LimerickIreland

Background: There is a paucity of data supporting the role of neutrophil-lymphocyte ratios (NLRs) to determine clinicopathological parameters in patients being treated for primary breast cancer. This study aims to evaluate the association between preoperative NLR and clinicopathological parameters in patients diagnosed with breast cancer.

Methods: A retrospective cohort study was performed. This included consecutive patients indicated to undergo surgery for primary breast cancer at University Hospital Limerick between January 2010–June 2017. NLR was expressed as a continuous variable. Univariable and multivariable linear regression analyses were used to determine the correlation between NLR and clinicopathological data. Data analytics was performed using SPSS v29.0.

Results: A total of 673 patients met the inclusion criteria. Overall, the median preoperative NLR of 2.63 (standard deviation: 1.42). At univariable analysis, patient age [beta coefficient: 0.009, 95% confidence interval (CI): 0.001–0.017, P=0.027], tumour size (beta coefficient: 0.013, 95% CI: 0.005–0.021, P=0.001), and human epidermal growth factor receptor-2 (HER2) status (beta coefficient: −0.370, 95% CI: −0.676 to −0.065, P=0.017) were all predicted using NLR. However, at multivariable analysis, tumour size was the sole parameter predictable by NLR (beta coefficient: 0.011, 95% CI: 0.002–0.019, P=0.013).

Conclusions: This study demonstrates that preoperative NLR may serve as an independent predictor of tumour size in patients being treated with primary breast cancer. Ratification of these preliminary findings is warranted before robustly adopted into clinical practice.

Keywords: Breast cancer; cancer; human epidermal growth factor receptor-2 (HER2); neutrophil-to-lymphocyte ratio; prognostic marker

Acknowledgments

Funding: None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

doi: 10.21037/map-24-ab033
Cite this abstract as: Isik B, Davey M, Jaffer A, Buckley J, Baban C, Merrigan BA, Tormey S. AB033. SOH24AB_089. Assessing the clinical utility of preoperative neutrophil-lymphocyte ratio as a predictor of clinicopathological parameters in patients being treated for primary breast cancer. Mesentery Peritoneum 2024;8:AB033.

Article Options

Download Citation

Share